Modality
Radioligand
MOA
SGLT2i
Target
DLL3
Pathway
STING
NB
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
~Mar 2017
→ ~Jun 2018
NDA/BLA
Sep 2018
→ Jun 2029
NDA/BLACurrent
NCT04291322
2,037 pts·NB
2019-05→2025-03·Terminated
NCT08998206
2,805 pts·NB
2018-09→2029-06·Completed
4,842 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-03-101.1y agoPh3 Readout· NB
2029-06-033.2y awayPh3 Readout· NB
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Complet…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2025-03-10 · 1.1y ago
NB
Ph3 Readout
2029-06-03 · 3.2y away
NB
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04291322 | NDA/BLA | NB | Terminated | 2037 | NT-proBNP |
| NCT08998206 | NDA/BLA | NB | Completed | 2805 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 |